Dose-adjusted EPOCH-R in patients with newly diagnosed diffuse large B-cell lymphoma harboring MYC rearrangement

J Clin Exp Hematop. 2020 Jun 20;60(2):60-61. doi: 10.3960/jslrt.20004. Epub 2020 May 13.
No abstract available

Keywords: MYC; diffuse large B-cell lymphoma; dose-adjusted EPOCH-R.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Gene Rearrangement / drug effects
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / genetics
  • Middle Aged
  • Prednisone / therapeutic use
  • Prospective Studies
  • Proto-Oncogene Proteins c-myc / genetics*
  • Rituximab / therapeutic use*
  • Vincristine / therapeutic use

Substances

  • Proto-Oncogene Proteins c-myc
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • EPOCH protocol